Indeed, it has already been shown that in humans, PTHrP (1–36) needs to be used at a dose 20 times higher than PTH to have the same anabolic effects, but at this high dose, PTHrP (1–36) causes hypercalcemia.(52). Here, PTH is linked to hypercalcemia disease.